Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity

Study acronym: MASLD
StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Mar 31, 2025 to Sep 30, 2025 Show 6 more changesShow less
    • Lead sponsor: The Third People's Hospital of Chengdu to The Third People's Hospital of Chengdu
    • Study completion date changed from estimate of Mar 31, 2025 to Jul 31, 2026
    • Trial completed
    • Enrollment target: estimated 600 to confirmed 565
    • Eligibility criteria expanded, about 11 words
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Trial Details
NCT Number NCT06720766
Lead Sponsor The Third People's Hospital of Chengdu
Conditions
(from sponsor)		 Fatty Liver Disease
Related terms Non-alcoholic Fatty Liver Disease
Enrollment 565 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov